DNLI Denali Therapeutics Inc.
$23.27 -0.92%
Healthcare · Biological Products, (No Diagnostic Substances)
Denali Therapeutics Inc. (DNLI) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $3.7 billion. Shares last traded at $23.27, 5.3% below their 52-week high. Over the past year the stock is up 66.9%.
Market Cap
$3.7B
Shares Out
158.7M
EPS (TTM)
$-5.21
P/E Ratio
—
P/S Ratio
—
P/B Ratio
3.99
Dividend / Share
—
Dividend Yield
—
52-Week High
$24.57
52-Week Low
$12.61
Volume
127,876
Avg Vol (3m)
108,474.571
Performance
1W
+10.73%
1M
+28.36%
3M
+17.74%
6M
+36.85%
YTD
+42.82%
1Y
+66.89%
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
67.78
SMA (50)
$19.99
SMA (200)
$18.37
Price vs SMA50
+16.39%
Price vs SMA200
+26.64%
ATR (14)
$1.37
Financials
Revenue
$0M
Net Income
$-513M
Gross Margin
—
Operating Margin
—
Net Margin
—
Return on Equity
-55.3%
Return on Assets
-40.5%
Current Ratio
9.28
Debt / Equity
0.37
Revenue Growth (YoY)
—
Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2026 | $-0.69 | 2026-05-07 |
| FY 2025 | $-2.97 | 2026-02-26 |
| Q3 2025 | $-2.24 | 2025-11-06 |
| Q2 2025 | $-1.50 | 2025-08-11 |
| Q1 2026 | $-0.78 | 2026-05-07 |
| FY 2025 | $-2.57 | 2026-02-26 |
Biological Products, (No Diagnostic Substances) peers
DNLI vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.
1–14 of 14
| AMGN | Amgen | $182.1B | 23.62 | 4.96 | 21.0% | -1.27% |
| GILD | Gilead Sciences | $153.5B | 18.04 | 5.21 | 28.9% | -1.46% |
| RVMD | Revolution Medicines, Inc. | $34.6B | -30.62 | — | — | +3.14% |
| BIIB | Biogen | $29.0B | 22.44 | 2.93 | 13.1% | -1.15% |
| MRNA | Moderna | $25.4B | -8.99 | — | — | +3.22% |
| NBIX | Neurocrine Biosciences Inc | $15.9B | 33.24 | 5.56 | 16.7% | -0.48% |
| EXEL | Exelixis, Inc. | $13.1B | 16.68 | 5.62 | 33.7% | -1.04% |
| KRYS | Krystal Biotech, Inc. | $10.2B | 50.02 | 26.33 | 52.6% | +1.68% |
| TECH | Bio-Techne | $9.1B | 123.61 | 7.44 | 6.0% | +5.36% |
| HALO | Halozyme Therapeutics, Inc. | $8.1B | 25.67 | 5.82 | 22.7% | -0.03% |
| IBRX | Immunitybio, Inc. | $7.7B | -21.87 | — | — | +5.01% |
| RGEN | Repligen Corp | $7.4B | 152.27 | 10.08 | 6.6% | -1.20% |
| KYMR | Kymera Therapeutics, Inc. | $7.4B | 23.88 | — | — | +0.44% |
| PCVX | Vaxcyte, Inc. | $7.4B | -9688.00 | — | — | +1.57% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.